Liver Diseases Therapeutics Market by Treatment (Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids), End User (Ambulatory Surgery Centers, Hospitals) - Global Forecast 2024-2030

Liver Diseases Therapeutics Market by Treatment (Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids), End User (Ambulatory Surgery Centers, Hospitals) - Global Forecast 2024-2030


The Liver Diseases Therapeutics Market size was estimated at USD 16.77 billion in 2023 and expected to reach USD 18.12 billion in 2024, at a CAGR 8.16% to reach USD 29.04 billion by 2030.

Global Liver Diseases Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liver Diseases Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Diseases Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Liver Diseases Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Endo International PLC, F. Hoffmann-La Roche AG, Gilead Science Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Protagonist Therapeutics, Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Liver Diseases Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment
Anti Viral Drugs

Chemotherapy Drugs

Corticosteroids

Immunoglobulin

Immunosuppressant Drugs

Targeted Therapy

End User
Ambulatory Surgery Centers

Hospitals

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Liver Diseases Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Diseases Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Liver Diseases Therapeutics Market?
4. What is the market share of the leading vendors in the Liver Diseases Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Liver Diseases Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Liver Diseases Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surge in the incidences of liver diseases worldwide
5.1.1.2. Increasing government and private organizations initiatives toward awareness and vaccination programs
5.1.1.3. Changing lifestyles such as consumption of alcohol and smoking
5.1.2. Restraints
5.1.2.1. Concerns over probable side effects of the medication
5.1.3. Opportunities
5.1.3.1. Ongoing research and development activities for prevention and cure of liver diseases
5.1.3.2. Increasing patent expiration of therapeutics
5.1.4. Challenges
5.1.4.1. Strict government regulations and high cost involved in R&D
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Liver Diseases Therapeutics Market, by Treatment
6.1. Introduction
6.2. Anti Viral Drugs
6.3. Chemotherapy Drugs
6.4. Corticosteroids
6.5. Immunoglobulin
6.6. Immunosuppressant Drugs
6.7. Targeted Therapy
7. Liver Diseases Therapeutics Market, by End User
7.1. Introduction
7.2. Ambulatory Surgery Centers
7.3. Hospitals
8. Americas Liver Diseases Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Liver Diseases Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.
10. South Korea
9.
11. Taiwan
9.
12. Thailand
9.
13. Vietnam
10. Europe, Middle East & Africa Liver Diseases Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.
10. Nigeria
10.
11. Norway
10.
12. Poland
10.
13. Qatar
10.
14. Russia
10.
15. Saudi Arabia
10.
16. South Africa
10.
17. Spain
10.
18. Sweden
10.
19. Switzerland
10.
20. Turkey
10.
21. United Arab Emirates
10.
22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Astellas Pharma Inc.
12.1.2. AstraZeneca PLC
12.1.3. Bayer AG
12.1.4. Bristol-Myers Squibb Company
12.1.5. Dicerna Pharmaceuticals, Inc.
12.1.6. Endo International PLC
12.1.7. F. Hoffmann-La Roche AG
12.1.8. Gilead Science Inc.
12.1.9. GlaxoSmithKline PLC
12.1.
10. Johnson & Johnson Services, Inc.
12.1.
11. Merck & Co. Inc.
12.1.
12. Novartis AG
12.1.
13. Pfizer Inc.
12.1.
14. Protagonist Therapeutics, Inc.
12.1.
15. Sanofi S.A.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
FIGURE 7. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 8. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings